natgillin/translations-raw huggingface dataset:
Rensselaer, NY 12144 United States
Rensselaer, NY 12144 ZDA
Rensselaer, NY 12144 USA
Rensselaer, NY 12144 ZDA
Renvela contains sevelamer carbonate as the active ingredient.
Zdravilo Renvela vsebuje sevelamerijev karbonat kot zdravilno učinkovino.
Renvela contains sevelamer, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium.
Zdravilo Renvela vsebuje sevelamer, neabsorbtiven premrežen polimer, ki veže fosfate in ne vsebuje kovin ali kalcija.
Renvela does not contain any calcium.
Zdravilo Renvela ne vsebuje kalcija.
Renvela film-coated tablets are white tablets with RENVELA 800 imprinted on one side.
Renvela filmsko obložene tablete so bele tablete z natisom RENVELA 800 vtisnjenim na eni strani.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.
Zdravilo Renvela je indicirano tudi za nadzor hiperfosfatemije pri odraslih bolnikih s kronično boleznijo ledvic, ki niso na dializi, in imajo raven fosforja v serumu ≥ 1,78 mmol/l.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus > 1.78 mmol/l.
Zdravilo Renvela je indicirano tudi za nadzor hiperfosfatemije pri odraslih bolnikih s kronično boleznijo ledvic, ki niso na dializi, in imajo raven serumskega fosforja ≥ 1,78 mmol/l.
Renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease patients not on dialysis with serum phosphorus > 1.78 mmol/l.
Zdravilo Renvela je indicirano tudi za nadzor hiperfosfatemije pri bolnikih s kronično boleznijo ledvic, ki niso na dializi, in imajo raven serumskega fosforja ≥ 1,78 mmol/l.
Renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
Zdravilo Renvela je indicirano za nadzor hiperfosfatemije pri odraslih bolnikih ki prejemajo hemodializo ali peritonealno dializo.
Renvela is not absorbed and may affect the bioavailability of other medicinal products.
Zdravilo Renvela se ne absorbira in lahko vpliva na biološko uporabnost drugih zdravil.
Renvela is not absorbed compound and may affect the bioavailability of other medicinal products.
Zdravilo Renvela se ne absorbira in lahko vpliva na biološko uporabnost drugih zdravil.
Renvela is not indicated for the control of hyperparathyroidism.
Zdravilo Renvela ni indicirano za nadzorovanje hiperparatiroidizma.
Renvela is unlikely to affect your ability to drive or to use machines.
Ni verjetno, da bi zdravilo Renvela vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
Renvela is used to control hyperphosphataemia (high blood phosphate levels) in: adult patients on dialysis (a blood clearance technique).
Zdravilo Renvela se uporablja za nadzor hiperfosfatemije (visoke ravni fosfata v krvi) pri: odraslih bolnikih na dializi (tehnika čiščenja krvi).
Renvela powder for oral suspension is a pale yellow powder supplied in a foil sachet with a heat seal.
Renvela prašek za peroralno suspenzijo je svetlorumeni prašek, na voljo v termično zvarjeni vrečki iz folije.
Renvela powder for oral suspension must be taken three times per day with meals.
Zdravilo Renvela prašek za peoralno suspenzijo je treba jemati trikrat na dan z obroki.
Renvela powder for oral suspension must be taken three times per day with meals.
Zdravilo Renvela prašek za suspenzijo je treba jemati trikrat dnevno z obroki.
Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Renvela se sme uporabljati sočasno s terapijo preprečevanja razvoja bolezni kosti, v sklopu katere se dodaja kalcij in vitamin D.
Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Zdravilo Renvela se sme uporabljati sočasno s terapijo preventive razvoja bolezni kosti pri kateri se dodaja kalcij in vitamin D.
Renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Zdravilo Renvela je treba uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijev dodatek, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog, za nadziranje razvoja renalne osteodistrofije.
Renvela should not be taken at the same time as ciprofloxacin (an antibiotic).
Zdravila Renvela ne smete jemati sočasno s ciprofloksacinom (antibiotik).
Renvela should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.
Zdravilo Renvela naj nosečnice uporabljajo le, če ga nujno potrebujejo, in po skrbni presoji razmerja med koristmi in tveganjem za mater in zarodek.
Renvela treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
Pri bolnikih, ki imajo hudo zaprtje ali druge hude gastrointestinalne simptome, je treba ponovno pretehtati smiselnost zdravljenja z zdravilom Renvela.
Reoccurrence of Thrombocytopenia
Ponovitev trombocitopenije
repaglinide
metadon
repaglinide (used to treat diabetes),
repaglinid (za zdravljenje sladkorne bolezni),
Repaglinide Accord 0.5 mg tablets Repaglinide
Repaglinide Accord 0,5 mg tablete Repaglinid
Repaglinide Accord 0.5 mg: Each tablet contains 0.5 mg repaglinide Repaglinide Accord 1 mg: Each tablet contains 1 mg repaglinide Repaglinide Accord 2 mg: Each tablet contains 2 mg repaglinide
Repaglinide Accord 0,5 mg: ena tableta vsebuje 0,5 mg repaglinida Repaglinide Accord 1 mg tablete: ena tableta vsebuje 1 mg repaglinida Repaglinide Accord 2 mg tablete: ena tableta vsebuje 2 mg repaglinida
Repaglinide Accord 1 mg tablets
Repaglinide Accord 1 mg tablete
Repaglinide Accord 1 mg tablets Repaglinide
Repaglinide Accord 1 mg tablete Repaglinid
Repaglinide Accord 2 mg tablets
Repaglinide Accord 2 mg tablete
Repaglinide Accord 2 mg tablets Repaglinide
Repaglinide Accord 2 mg tablete repaglinid
Repaglinide Accord has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.
Zdravilo Repaglinide Accord nima neposrednega vpliva na sposobnost vožnje in upravljanja s stroji, vendar pa lahko povzroči hipoglikemijo.
Repaglinide Accord is a ‘generic medicine’.
Zdravilo Repaglinid Accord je „generično zdravilo“.
Repaglinide Accord repaglinide
Repaglinid Accord repaglinid
Repaglinide Accord with alcohol
Zdravilo Repaglinide Accord skupaj z alkoholom
Repaglinide has been given with weekly escalating doses from 4 – 20 mg four times daily in a 6 week period.
Repaglinid so uporabljali v tedensko naraščajočih odmerkih od 4 do 20 mg štirikrat na dan 6 tednov.
Repaglinide is . not affected by renal disorders (see section 5.2).
Bolezni ledvic ne vplivajo na repaglinid (glejte poglavje 5.2).
Repaglinide is given preprandially and is titrated individually to optimise glycaemic control.
Repaglinid se uporablja predprandialno in ga je treba za optimiranje urejenosti glukoze v krvi individualno prilagoditi.
Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.
Uporaba repaglinida je indicirana pri odraslih bolnikih s sladkorno boleznijo tipa 2, pri katerih hiperglikemije ni več mogoče zadovoljivo obvladovati z dieto, zmanjšanjem telesne mase in telesno dejavnostjo.
Repaglinide Krka 0.5 mg tablets
Repaglinide Krka 0,5 mg tablete
Repaglinide Krka 0.5 mg tablets Repaglinide
Repaglinide Krka 0,5 mg tablete repaglinid
Repaglinide Krka 1 mg tablets
Repaglinide Krka 1 mg tablete
Repaglinide Krka 1 mg tablets Repaglinide
Repaglinide Krka 1 mg tablete repaglinid
Repaglinide Krka 2 mg tablets Repaglinide
Repaglinide Krka 2 mg tablete repaglinid
Repaglinide Krka is a ‘generic medicine’.
Repaglinid Krka je „generično zdravilo“.
Repaglinide Krka with alcohol
Zdravila Repaglinide Krka skupaj z alkoholom
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 98%).
Za farmakokinetiko repaglinida je značilen majhen volumen porazdelitve (30 l), kar je v skladu s porazdelitvijo v znotrajcelični tekočini, vezava na plazemske proteine pri človeku pa je obsežna (več kot 98 %).
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 98%).
Za farmakokinetiko repaglinida je značilen majhen volumen porazdelitve (30 l), kar je v skladu s porazdelitvijo v znotrajcelični tekočini, vezava na plazemske proteine pri človeku pa je obsežna (več kot 98 %)..
Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid), and is highly bound to plasma proteins in humans (greater than 98%).
Za farmakokinetiko repaglinida je značilen majhen volumen porazdelitve (30 l), kar je v skladu s porazdelitvijo v znotrajcelični tekočini, vezava na plazemske proteine pri človeku pa je obsežna (več kot 98 %).
Repaglinide tablets are yellow, round and convex and engraved with Novo Nordisk logo (Apis bull).
Tablete repaglinida so rumene, okrogle, izbočene in imajo vrezan logo družbe Novo Nordisk (bik Apis).
Repaglinide Teva
Repaglinid Teva
Repaglinide Teva 0.5 mg tablet is a light blue to blue, capsule shaped tablet, debossed with "93" on one side and “210” on the other side of the tablet.
Zdravilo Repaglinid Teva 0,5 mg tablete je svetlo modra do modra tableta v obliki kapsule, z vgraviranim napisom “93” na eni strani in “210” na drugi strani tablete.
Repaglinide Teva is a ‘generic medicine’.
Repaglinid Teva je „generično zdravilo“.
Repaglinide Teva is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).
Zdravilo Repaglinid Teva je peroralni antidiabetik z repaglinidom, ki trebušni slinavki pomaga, da tvori več insulina, in tako znižuje sladkor v krvi (glukozo).
repaglinide – a medicine used to treat diabetes
repaglinid – zdravilo za zdravljenje sladkorne bolezni,
repaglinide, glibenclamide (used to treat high blood sugar)
repaglinid, glibenklamid (za zdravljenje visokih ravni krvnega sladkorja)
Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia.
Tako kot drugi sekretagogi insulina lahko tudi repaglinid povzroči hipoglikemijo.
repaglinide, medicine to treat diabetes paclitaxel, medicine to treat cancer.
repaglinid, zdravilo za zdravljenje sladkorne bolezni, paklitaksel, zdravilo za zdravljenje raka.
repaglinide, medicine to treat diabetes, paclitaxel, medicine to treat cancer.
repaglinid, za zdravljneje sladkorne bolezni, paklitaksel, za zdravljenje raka.
repaglinide, medicine to treat diabetes, paclitaxel, medicine to treat cancer.
repaglinid, zdravilo za zdravljenje sladkorne bolezni, paklitaksel, zdravilo za zdravljenje raka.
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
repaglinid, pioglitazon, nateglinid ali rosiglitazon za sladkorno bolezen,
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
repaglinid, pioglitazon, nateglinid, ali rosiglitazon za sladkorno bolezen,
repaglinide, pioglitazone, nateglinide, or rosiglitazone for diabetes
repaglinid, pioglitazon, nateglinid, ali rosiglitazon za zdravljenej sladkorne bolezni,
Repaglinide: AUC: ↑ 1.2-fold
Repaglinid: AUC: ↑ 1,2-krat
Repair of single symptomatic cartilage defects of the femoral condyle of the knee (International Cartilage Repair Society [ICRS] grade III or IV) in adults.
Zdravljenje posameznih simptomatskih okvar hrustanca femoralnega kondila kolena (stopnja III ali IV po Mednarodni organizaciji za zdravljenje hrustanca (International Cartilage Repair Society [ICRS]) pri odraslih.
Repatha 140 mg solution for injection evolocumab
Repatha 140 mg raztopina za injiciranje evolokumab
Repatha 140 mg solution for injection in pre-filled pen
Repatha 140 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku
Repatha 140 mg solution for injection in pre-filled pen evolocumab
Repatha 140 mg raztopina za injiciranje v napolnjenem injekcijskem peresniku evolokumab
Repatha 140 mg solution for injection in pre-filled syringe
Repatha 140 mg raztopina za injiciranje v napolnjeni injekcijski brizgi
Repatha 140 mg solution for injection in pre-filled syringe evolocumab
Repatha 140 mg raztopina za injiciranje v napolnjeni injekcijski brizgi evolokumab
Repatha 140 pen
Repatha 140 peresnik
Repatha 140 syringe
Repatha 140 brizga
Repatha at either dose was effective in all subgroups relative to placebo and ezetimibe, with no notable differences observed between subgroups, such as age, race, gender, region, body-mass index, National Cholesterol Education Program risk, current smoking status, baseline coronary heart disease (CHD) risk factors, family history of premature CHD, glucose tolerance status, (i.e., diabetes mellitus type 2, metabolic syndrome, or neither), hypertension, statin dose and intensity, unbound baseline PCSK9, baseline LDL-C and baseline TG.
Zdravilo Repatha je bilo v primerjavi s placebom in ezetimibom v enem in drugem odmerku učinkovito v vseh podskupinah: zabeležili niso nobenih opaznih razlik med podskupinami, npr. glede na starost, raso, spol, regijo, indeks telesne mase, tveganje po NCEP (Nationa l Cholesterol Education Program), trenutni kadilski status, izhodiščne dejavnike tveganja za koronarno bolezen srca (KBS), družinsko anamnezo prezgodnje KBS, status tolerance za glukozo (tj. sladkorno bolezen tipa 2, metabolični sindrom ali nič od tega), hipertenzijo, odmerek in intenzivnost statinov, nevezani izhodiščni PCSK9, izhodiščni LDL-H in izhodiščne trigliceride.
Repatha at either dose was effective in all subgroups relative to placebo and ezetimibe, with no notable differences observed between subgroups, such as age, race, gender, region, body-mass index, National Cholesterol Education Program risk, current smoking status, baseline coronary heart disease (CHD) risk factors, family history of premature CHD, glucose tolerance status, (i.e., diabetes mellitus type 2, metabolic syndrome, or neither), hypertension, statin dose and intensity, unbound baseline PCSK9, baseline LDL-C and baseline TG.
Zdravilo Repatha je bilo v primerjavi s placebom in ezetimibom v enem in drugem odmerku učinkovito v vseh podskupinah: zabeležili niso nobenih opaznih razlik med podskupinami, npr. glede na starost, raso, spol, regijo, indeks telesne mase, tveganje po NCEP (National Cholesterol Education Program), trenutni kadilski status, izhodiščne dejavnike tveganja za koronarno bolezen srca (KBS), družinsko anamnezo prezgodnje KBS, status tolerance za glukozo (tj. sladkorno bolezen tipa 2, metabolični sindrom ali nič od tega), hipertenzijo, odmerek in intenzivnost statinov, nevezani izhodiščni PCSK9, izhodiščni LDL-H in izhodiščne trigliceride.
Repatha contains the active substance evolocumab.
Zdravilo Repatha vsebuje zdravilno učinkovino evolokumab.
Repatha has no known influence on the ability to drive and use machines.
Zdravilo Repatha nima znanega vpliva na sposobnost vožnje in upravljanja s stroji.
Repatha has no or negligible influence on the ability to drive and use machines.
Zdravilo Repatha ne vpliva ali le zanemarljivo vpliva na sposobnost vožnje in upravljanja s stroji.
Repatha has not been studied in patients with severe renal impairment (see section 4.4).
Pri bolnikih s hudo okvaro ledvic zdravilo Repatha ni raziskano (glejte poglavje 4.4).
Repatha is a human IgG2 monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells.
Zdravilo Repatha je človeško monoklonsko protitelo IgG2, pridobljeno s tehnologijo rekombinantne DNA v celicah jajčnika kitajskega hrčka (CHO – Chinese hamster ovary).
Repatha is a medicine that lowers levels of ’bad’ cholesterol, a type of fat, in the blood.
Zdravilo Repatha je zdravilo, ki znižuje "slabi" holesterol, vrsto maščobe v krvi.
Repatha is a medicine used to treat:
Zdravilo Repatha se uporablja za zdravljenje:
Repatha is also used to treat mixed dyslipidaemia (abnormal levels of fats in blood, including high levels of LDL-cholesterol).
Zdravilo Repatha se uporablja tudi za zdravljenje mešane dislipidemije (nenormalnih ravni maščob v krvi, vključno z visokimi ravnmi holesterola LDL).
Repatha is available as a solution for injection in a pre-filled syringe or pre-filled pen (140 mg).
Zdravilo Repatha je na voljo kot raztopina za injiciranje v napolnjeni injekcijski brizgi ali napolnjenem injekcijskem peresniku (140 mg).
Repatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet: in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.
Zdravilo Repatha je indicirano pri odraslih s primarno hiperholesterolemijo (heterozigotno družinsko in nedružinsko) ali mešano dislipidemijo, kot dodatek dieti: v kombinaciji s statinom ali statinom z drugimi zdravili za zniževanje lipidov pri bolnikih, ki ne morejo doseči ciljnega holesterola LDL z največjim toleriranim odmerkom statina, ali samo ali v kombinaciji z drugimi zdravili za zniževanje lipidov pri bolnikih, ki ne prenašajo statinov, ali pri katerih so statini kontraindicirani.
Repatha is to be used together with a low-fat diet, in the following cases:
Zdravilo Repatha se skupaj z dieto z malo maščobami uporablja na naslednje načine:
Repatha is used in addition to your cholesterol lowering diet if you are: an adult with a high cholesterol level in your blood (primary hypercholesterolaemia [heterozygous familial and non-familial] or mixed dyslipidaemia).
Zdravilo Repatha uporabljamo poleg diete za zniževanje holesterola, če ste: odrasla oseba z visokim holesterolom v krvi (imate primarno hiperholesterolemijo [heterozigotno družinsko in nedružinsko] ali mešano dislipidemijo).
Repatha reduced LDL-C, non-HDL-C, Apo B, TC, Lp(a), VLDL-C, TG, TC/HDL-C, and ApoB/ApoA1and increased HDL-C in patients with mixed dyslipidaemia.
Bolnikom z mešano dislipidemijo je zdravilo Repatha znižalo LDL-H, ne-HDL-H, ApoB, TC, Lp(a), VLDL-H, trigliceride, TC/HDL-H in ApoB/ApoA1 ter zvišalo HDL-H.
Repatha should be used with caution in patients with severe hepatic impairment.
Pri bolnikih s hudo okvaro jeter je treba zdravilo Repatha uporabljati previdno.
Repatha should be used with caution in patients with severe renal impairment.
Pri bolnikih s hudo okvaro ledvic je treba zdravilo Repatha uporabljati previdno.
Repatha significantly reduced LDL-C from baseline at week 12 compared with control (nominal p < 0.001).
Zdravilo Repatha je v primerjavi s kontrolo značilno znižalo LDL-H od izhodišča do 12. tedna (nominalni p < 0,001).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared to ezetimibe (p < 0.001) (see table 3).
Zdravilo Repatha je od izhodišča do povprečja 10. in 12. tedna v primerjavi z ezetimibom značilno znižalo TC, ApoB, ne-HDL-H, TC/HDL-H, ApoB/ApoA1 in Lp(a) (p < 0,001) (glejte tabelo 3).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001) (see table 3).
Repatha je od izhodišča do povprečja 10. in 12. tedna tako v primerjavi s placebom kot z ezetimibom značilno znižalo TC, ApoB, ne-HDL-H, TC/HDL-H, ApoB/ApoA1 in Lp(a) (p < 0,001) (glejte tabelo 3).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1 and Lp(a), from baseline to mean of weeks 10 and 12 compared with both placebo and ezetimibe (p < 0.001) (see table 3).
Zdravilo Repatha je od izhodišča do povprečja 10. in 12. tedna tako v primerjavi s placebom kot z ezetimibom značilno znižalo TC, ApoB, ne-HDL-H, TC/HDL-H, ApoB/ApoA1 in Lp(a) (p < 0,001) (glejte tabelo 3).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a) , and increased HDL-C and ApoA1 from baseline to week 52 in OSLER and to week 24 in OSLER-2 compared with control (nominal p < 0.001).
Zdravilo Repatha je v primerjavi s kontrolno skupino značilno znižalo TC, ApoB, ne-HDL-H, TC/HDL-H, ApoB/ApoA1, VLDL-H, trigliceride in Lp(a) ter zvišalo HDL-H in ApoA1 od izhodišča do 52. tedna v študiji OSLER in do 24. tedna v študiji OSLER-2 (nominalni p < 0,001).
Repatha significantly reduced TC, ApoB, non-HDL-C, TC/HDL-C, ApoB/ApoA1, VLDL-C, TG and Lp(a), and increased HDL-C and ApoA1 at week 52 compared with placebo (p < 0.001) (table 4).
Zdravilo Repatha je 52. teden v primerjavi s placebom značilno znižalo TC, ApoB, ne-HDL-H, TC/HDL-H, ApoB/ApoA1, VLDL-H, trigliceride in Lp(a) ter zvišalo HDL-H in ApoA1 (p < 0,001) (glejte tabelo 4).
Repatha single use pre-filled syringe
Repatha napolnjena injekcijska brizga za enkratno uporabo
Repatha single use SureClick pre-filled pen
Repatha napolnjeni injekcijski peresnik SureClick za enkratno uporabo
Repatha was superior to ezetimibe in reducing LDL-C, TC, ApoB, non-HDL-C, Lp(a), TC/HDL-C, and ApoB/ApoA1.
Zdravilo Repatha je bolj kot ezetimib znižalo LDL-H, TC, ApoB, ne-HDL-H, Lp(a), TC/HDL-H in ApoB/ApoA1.
Repeat administration every 12 months to maintain efficacy.
Zdravilo dajte vsakih 12 mesecev, da se bo učinkovitost vzdrževala.
Repeat administration every 6 months to maintain efficacy.
Zdravilo dajte vsakih šest mesecev, da se bo učinkovitost vzdrževala.
Repeat at intervals of 24 hours until the bleed stops.
Ponavljajte v 24-urnih intervalih, dokler se krvavitev ne ustavi.
Repeat cycle
krog ponavljajte
Repeat dose administration of fosamprenavir (700 mg twice daily x
Pri uporabi ponavljajočih se odmerkov fosamprenavirja (700 mg dvakrat na dan
Repeat doses should be considered when a patient experiences a response to treatment followed subsequently by a loss in visual acuity and in the physician’s opinion may benefit from retreatment without being exposed to significant risk (see section 5.1).
O ponovnem odmerjanjuje treba razmisliti, kadar se bolnik odzove na zdravljenje, nato pa se mu ostrina vida zmanjša, pri tem pa ponovno zdravljenje po mnenju zdravnika lahko koristi bolniku, ne da bi bil ta izpostavljen znatnemu tveganju (glejte poglavje 5.1).
Repeat Evaluation (N=23)
Ponovna ocena (N = 23)
Repeat every 12 to 24 hours.
12 - 24 ur.
Repeat every 12 to 24 hours.
Endurtaka á gjöf á 12 til 24 klst. fresti.
Repeat every 12 to 24 hours.
Ponavljajte vsakih 12 do 24 ur,
Repeat every 24 hours.
telesna masa (v kg)
Repeat every 24 – 72 hours for the first week, and then maintenance dose 1 – 2 times per week until bleeding stops and healing is achieved.
Ponovite vsakih 24 – 72 ur v prvem tednu, nato uvedite vzdrževalni odmerek 1-2 krat na teden, dokler krvavitev ne preneha in pride do celjenja.
Repeat every 24 – 72 hours for the first week, and then maintenance dose weekly until bleeding stops and healing is achieved.
Ponovite vsakih 24 – 72 ur v prvem tednu, nato uvedite vzdrževalni odmerek tedensko, dokler krvavitev ne preneha in pride do celjenja.
Repeat infusion every 12 - 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Ponovite infundiranje na vsakih 12 - 24 ur, vsaj 1 dan, dokler krvavitev, sodeč po bolečini, ne preneha ali dokler se ne zaceli.
Repeat infusion every 12 to 24 hours for at least 1 day, until the bleeding episode as indicated by pain is resolved or healing is achieved.
Ponovite infundiranje na vsakih 12 - 24 ur, vsaj 1 dan, dokler krvavitev, sodeč po bolečini, ne preneha ali dokler se ne zaceli.
Repeat infusion every 12-24 hours for 3 - 4 days or more until pain and acute disability are resolved.
Ponovite infundiranje na vsakih 12 - 24 ur, 3 - 4 dni ali dlje, dokler bolečina in akutna nezmožnost ne izzvenita.